Bortezomib-based induction intensification improves DpR, PFS in MM
14 Jan 2020
bởiAudrey Abella
Patients with newly diagnosed multiple myeloma (MM) with suboptimal response to an immunomodulatory triplet regimen benefited from a response-adapted intensification regimen with cyclophosphamide, bortezomib, and dexamethasone (CVD), leading to improved depth of response (DpR) and progression-free survival (PFS), according to outcomes from the Myeloma XI trial.